IL-17 in psoriasis: Implications for therapy and cardiovascular co-morbidities

Cytokine

Volumn 62, Issue 2, 2013, Pages 195-201

  Golden, Jackelyn B ^a   McCormick, Thomas S ^a,b   Ward, Nicole L ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Cardiovascular disease; IL 17A; Psoriasis; Skin; Th17

Indexed keywords

ABATACEPT; ALEFACEPT; ANTIPSORIASIS AGENT; BRODALUMAB; CD3 ANTIBODY; CD4 ANTIBODY; COLECALCIFEROL; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DENILEUKIN DIFTITOX; DITHRANOL; ETRETIN; HU MAX; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 23; IXEKIZUMAB; METHOTREXATE; MK 3222; PLACEBO; RETINOL; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ARTERY THROMBOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; DISEASE ASSOCIATION; DRUG MECHANISM; HELPER CELL; HUMAN; INTERLEUKIN 17A GENE; LOW LEVEL LASER THERAPY; LYMPHOCYTE FUNCTION; NONHUMAN; PATHOPHYSIOLOGY; PHOTOTHERAPY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; PSORIASIS; PUVA; REVIEW; RISK FACTOR; TH17 CELL; TH22 CELL; ANTIGEN PRESENTING CELL; COMPLICATION; ENDOTHELIUM CELL; IMMUNOLOGY; INFLAMMATION; KERATINOCYTE; METABOLISM; MONOCYTE; TH1 CELL;

ANTIGEN-PRESENTING CELLS; CARDIOVASCULAR DISEASES; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; INTERLEUKIN-17; KERATINOCYTES; MONOCYTES; PSORIASIS; TH1 CELLS; TH17 CELLS;

EID: 84876816203     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.03.013     Document Type: Review

References (117)

1. Ellis C.N., Gorsulowsky D.C., Hamilton T.A., Billings J.K., Brown M.D., Headington J.T., et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986, 256:3110-3116.
2. Zheng Y., Danilenko D.M., Valdez P., Kasman I., Eastham-Anderson J., Wu J., et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445:648-651.
3. Wilson N.J., Boniface K., Chan J.R., McKenzie B.S., Blumenschein W.M., Mattson J.D., et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007, 8:950-957.
4. Kagami S., Rizzo H.L., Lee J.J., Koguchi Y., Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010, 130:1373-1383.
5. Eyerich S., Eyerich K., Pennino D., Carbone T., Nasorri F., Pallotta S., et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009, 119:3573-3585.
6. Davidovici B.B., Sattar N., Prinz J., Puig L., Emery P., Barker J.N., et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010, 130:1785-1796.
7. Kim N., Thrash B., Menter A. Comorbidities in psoriasis patients. Semin Cutan Med Surg 2010, 29:10-15.
8. Mehta N.N., Yu Y., Pinnelas R., Krishnamoorthy P., Shin D.B., Troxel A.B., et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011, 124:775 e1-6.
9. Ahlehoff O., Gislason G.H., Lindhardsen J., Charlot M.G., Jorgensen C.H., Olesen J.B., et al. Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study. PLoS One 2011, 6:e18125.
10. Ahlehoff O., Gislason G.H., Charlot M., Jorgensen C.H., Lindhardsen J., Olesen J.B., et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011, 270:147-157.
11. Mehta N.N., Azfar R.S., Shin D.B., Neimann A.L., Troxel A.B., Gelfand J.M. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database. Eur Heart J 2010, 31:1000-1006.
12. Vena G.A., Altomare G., Ayala F., Berardesca E., Calzavara-Pinton P., Chimenti S., et al. Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care database. Eur J Dermatol 2010, 20:593-598.
13. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B. Risk of myocardial infarction in patients with psoriasis. JAMA 2006, 296:1735-1741.
14. Kurd S.K., Gelfand J.M. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 2009, 60:218-224.
15. Griffiths C.E., Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet 2007, 370:263-271.
16. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N Engl J Med 2009, 361:496-509.
17. Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 2007, 445:866-873.
18. Detmar M., Brown L.F., Claffey K.P., Yeo K.T., Kocher O., Jackman R.W., et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994, 180:1141-1146.
19. Fortune D.G., Main C.J., O'Sullivan T.M., Griffiths C.E. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997, 137:755-760.
20. O'Brien M., Koo J. The mechanism of lithium and beta-blocking agents in inducing and exacerbating psoriasis. J Drugs Dermatol 2006, 5:426-432.
21. Naldi L., Peli L., Parazzini F., Carrel C.F. Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case-control study. J Am Acad Dermatol 2001, 44:433-438.
22. Penaranda C., Tang Q., Bluestone J.A. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol 2011, 187:2015-2022.
23. Ellis C.N., Fradin M.S., Messana J.M., Brown M.D., Siegel M.T., Hartley A.H., et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991, 324:277-284.
24. Lowes M.A., Chamian F., Abello M.V., Fuentes-Duculan J., Lin S.L., Nussbaum R., et al. Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 2005, 102:19057-19062.
25. Toichi E., Torres G., McCormick T.S., Chang T., Mascelli M.A., Kauffman C.L., et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006, 177:4917-4926.
26. Ellis C.N., Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001, 345:248-255.
27. Gottlieb S.L., Gilleaudeau P., Johnson R., Estes L., Woodworth T.G., Gottlieb A.B., et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995, 1:442-447.
28. Stevens L., Stocken L.A. Studies on enzymes involved in nucleic acid metabolism in foetal, young and regenerating rat liver. Biochem J 1963, 87:12-15.
29. Clark R.A. Skin-resident T cells: the ups and downs of on site immunity. J Invest Dermatol 2010, 130:362-370.
30. Clark R.A., Chong B., Mirchandani N., Brinster N.K., Yamanaka K., Dowgiert R.K., et al. The vast majority of CLA+ T cells are resident in normal skin. J Immunol 2006, 176:4431-4439.
31. Boyman O., Hefti H.P., Conrad C., Nickoloff B.J., Suter M., Nestle F.O. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 2004, 199:731-736.
32. Krueger G.G., Ellis C.N. Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br J Dermatol 2003, 148:784-788.
33. Zaba L.C., Cardinale I., Gilleaudeau P., Sullivan-Whalen M., Suarez-Farinas M., Fuentes-Duculan J., et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007, 204:3183-3194.
34. Caproni M., Antiga E., Melani L., Volpi W., Del Bianco E., Fabbri P. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 2009, 29:210-214.
35. Reddy M., Davis C., Wong J., Marsters P., Pendley C., Prabhakar U. Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275. Cell Immunol 2007, 247:1-11.
36. Jones S.A., Sutton C.E., Cua D., Mills K.H. Therapeutic potential of targeting IL-17. Nat Immunol 2012, 13:1022-1025.
37. Leonardi C., Matheson R., Zachariae C., Cameron G., Li L., Edson-Heredia E., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012, 366:1190-1199.
38. Papp K.A., Leonardi C., Menter A., Ortonne J.P., Krueger J.G., Kricorian G., et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012, 366:1181-1189.
39. Van Hauwermeiren F., Vandenbroucke R.E., Libert C. Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine Growth Factor Rev 2011, 22:311-319.
40. Aggarwal B.B., Gupta S.C., Kim J.H. Historical perspectives on tumor necrosis factor and its superfamily: 25years later, a golden journey. Blood 2012, 119:651-665.
41. Krueger G.G., Langley R.G., Leonardi C., Yeilding N., Guzzo C., Wang Y., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007, 356:580-592.
42. Papp K.A., Langley R.G., Lebwohl M., Krueger G.G., Szapary P., Yeilding N., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008, 371:1675-1684.
43. Gottlieb A.B., Cooper K.D., McCormick T.S., Toichi E., Everitt D.E., Frederick B., et al. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin 2007, 23:1081-1092.
44. Kauffman C.L., Aria N., Toichi E., McCormick T.S., Cooper K.D., Gottlieb A.B., et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004, 123:1037-1044.
45. Torti D.C., Feldman S.R. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 2007, 57:1059-1068.
46. Brownell I. Sexy and 17: TH17 effector T cells and psoriasis. J Drugs Dermatol 2007, 6:853-856.
47. Lowes M.A., Kikuchi T., Fuentes-Duculan J., Cardinale I., Zaba L.C., Haider A.S., et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008, 128:1207-1211.
48. Ma H.L., Liang S., Li J., Napierata L., Brown T., Benoit S., et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008, 118:597-607.
49. Nograles K.E., Zaba L.C., Guttman-Yassky E., Fuentes-Duculan J., Suarez-Farinas M., Cardinale I., et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008.
50. Zaba L.C., Fuentes-Duculan J., Eungdamrong N.J., Abello M.V., Novitskaya I., Pierson K.C., et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 2008.
51. Nograles K.E., Zaba L.C., Guttman-Yassky E., Fuentes-Duculan J., Suarez-Farinas M., Cardinale I., et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008, 159:1092-1102.
52. Schlaak J.F., Buslau M., Jochum W., Hermann E., Girndt M., Gallati H. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994, 102:145-149.
53. Austin L.M., Ozawa M., Kikuchi T., Walters I.B., Krueger J.G. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999, 113:752-759.
54. Uyemura K., Yamamura M., Fivenson D.F., Modlin R.L., Nickoloff B.J. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993, 101:701-705.
55. Bowcock A.M., Shannon W., Du F., Duncan J., Cao K., Aftergut K., et al. Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet 2001, 10:1793-1805.
56. Zhang L., Yang X.Q., Cheng J., Hui R.S., Gao T.W. Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity. Clin Immunol 2010, 135:108-117.
57. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
58. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141.
59. Chen Z., O'Shea J.J. Th17 cells: a new fate for differentiating helper T cells. Immunol Res 2008.
60. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 Cells. Annu Rev Immunol 2009, 27:485-517.
61. Fujishima S., Watanabe H., Kawaguchi M., Suzuki T., Matsukura S., Homma T., et al. Involvement of IL-17F via the induction of IL-6 in psoriasis. Arch Dermatol Res 2010, 302:499-505.
62. Trifari S., Kaplan C.D., Tran E.H., Crellin N.K., Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009, 10:864-871.
63. Zhang L., Li J.M., Liu X.G., Ma D.X., Hu N.W., Li Y.G., et al. Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis. J Clin Immunol 2011, 31:606-614.
64. Duhen T., Geiger R., Jarrossay D., Lanzavecchia A., Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009, 10:857-863.
65. Boniface K., Guignouard E., Pedretti N., Garcia M., Delwail A., Bernard F.X., et al. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 2007, 150:407-415.
66. Tohyama M., Hanakawa Y., Shirakata Y., Dai X., Yang L., Hirakawa S., et al. IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression. Eur J Immunol 2009, 39:2779-2788.
67. Wolk K., Kunz S., Witte E., Friedrich M., Asadullah K., Sabat R. IL-22 increases the innate immunity of tissues. Immunity 2004, 21:241-254.
68. Di Cesare A., Di Meglio P., Nestle F.O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009, 129:1339-1350.
69. Bettelli E., Oukka M., Kuchroo V.K. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007, 8:345-350.
70. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240.
71. Zhou L., Ivanov I.I., Spolski R., Min R., Shenderov K., Egawa T., et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007, 8:967-974.
72. Ramirez J.M., Brembilla N.C., Sorg O., Chicheportiche R., Matthes T., Dayer J.M., et al. al. Activation of the aryl hydrocarbon receptor reveals distinct requirements for IL-22 and IL-17 production by human T helper cells. Eur J Immunol 2010, 40:2450-2459.
73. Guttman-Yassky E., Lowes M.A., Fuentes-Duculan J., Zaba L.C., Cardinale I., Nograles K.E., et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol 2008, 181:7420-7427.
74. Tonel G., Conrad C., Laggner U., Di Meglio P., Grys K., McClanahan T.K., et al. Cutting edge: a critical functional role for IL-23 in psoriasis. J Immunol 2010, 185:5688-5691.
75. Lee E., Trepicchio W.L., Oestreicher J.L., Pittman D., Wang F., Chamian F., et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004, 199:125-130.
76. Piskin G., Sylva-Steenland R.M., Bos J.D., Teunissen M.B. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006, 176:1908-1915.
77. Harper E.G., Guo C., Rizzo H., Lillis J.V., Kurtz S.E., Skorcheva I., et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 2009, 129:2175-2183.
78. Res P.C., Piskin G., de Boer O.J., van der Loos C.M., Teeling P., Bos J.D., et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 2010, 5:e14108.
79. Lin A.M., Rubin C.J., Khandpur R., Wang J.Y., Riblett M., Yalavarthi S., et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011, 187:490-500.
80. Laggner U., Di Meglio P., Perera G.K., Hundhausen C., Lacy K.E., Ali N., et al. Identification of a novel proinflammatory human skin-homing Vgamma9Vdelta2 T cell subset with a potential role in psoriasis. J Immunol 2011, 187:2783-2793.
81. Cai Y., Shen X., Ding C., Qi C., Li K., Li X., et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity 2011, 35:596-610.
82. Hijnen D., Knol E.F., Gent Y.Y., Giovannone B., S J.P.B., Kupper T.S., et al. CD8(+) T Cells in the Lesional Skin of Atopic Dermatitis and Psoriasis Patients Are an Important Source of IFN-gamma, IL-13, IL-17, and IL-22. J Invest Dermatol 2012.
83. + T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol 2009, 86:435-443.
84. Feldman S.R., Krueger G.G. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005, 64(Suppl. 2). [ii65-8; discussion ii69-73].
85. Gaffen S.L. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009, 9:556-567.
86. Gaffen S.L. Recent advances in the IL-17 cytokine family. Curr Opin Immunol 2011, 23:613-619.
87. Mallbris L., Akre O., Granath F., Yin L., Lindelof B., Ekbom A., et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004, 19:225-230.
88. Mallbris L., Granath F., Hamsten A., Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006, 54:614-621.
89. Abuabara K., Azfar R.S., Shin D.B., Neimann A.L., Troxel A.B., Gelfand J.M. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK. Br J Dermatol 2010, 163:586-592.
90. Armstrong A.W., Schupp C., Bebo B. Psoriasis comorbidities: results from the national psoriasis foundation surveys 2003 to 2011. Dermatology 2012, 225:121-126.
91. Mehta N.N., Yu Y., Pinnelas R., Krishnamoorthy P., Shin D.B., Troxel A.B., et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011, 124. 775 e1-6.
92. Armstrong A.W., Harskamp C.T., Armstrong E.J. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 2013.
93. Gelfand J.M., Yeung H. Metabolic syndrome in patients with psoriatic disease. J Rheumatol Suppl 2012, 89:24-28.
94. Langan S.M., Seminara N.M., Shin D.B., Troxel A.B., Kimmel S.E., Mehta N.N., et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2012, 132:556-562.
95. Ahlehoff O., Gislason G.H., Lindhardsen J., Charlot M.G., Jorgensen C.H., Olesen J.B., et al. Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study. PLoS One 2011, 6:e18125.
96. Armstrong A.W., Harskamp C.T., Armstrong E.J. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens 2012.
97. Gelfand J.M., Dommasch E.D., Shin D.B., Azfar R.S., Kurd S.K., Wang X., et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009, 129:2411-2418.
98. Ahlehoff O., Gislason G.H., Jorgensen C.H., Lindhardsen J., Charlot M., Olesen J.B., et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish nationwide cohort study. Eur Heart J 2012, 33:2054-2064.
99. Armstrong A.W., Harskamp C.T., Ledo L., Rogers J.H., Armstrong E.J. Coronary artery disease in patients with psoriasis referred for coronary angiography. Am J Cardiol 2012, 109:976-980.
100. Lu Y., Chen H., Nikamo P., Qi Low H., Helms C., Seielstad M., et al. Association of cardiovascular and metabolic disease genes with psoriasis. J Invest Dermatol 2012.
101. Boehncke W.H., Boehncke S. Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. Curr Rheumatol Rep 2012, 14:343-348.
102. Boehncke W.H., Boehncke S., Tobin A.M., Kirby B. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011, 20:303-307.
103. Wolfram J.A., Diaconu D., Hatala D.A., Rastegar J., Knutsen D.A., Lowther A., et al. Keratinocyte but not endothelial cell-specific overexpression of Tie2 leads to the development of psoriasis. Am J Pathol 2009, 174:1443-1458.
104. Wang Y., Gao H., Loyd C.M., Fu W., Diaconu D., Liu S., et al. Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. J Invest Dermatol 2012, 132:2067-2075.
105. Ward N.L., Loyd C.M., Wolfram J.A., Diaconu D., Michaels C.M., McCormick T.S. Depletion of antigen-presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice. Br J Dermatol 2011, 164:750-758.
106. Ward N.L., Kavlick K.D., Diaconu D., Dawes S.M., Michaels K.A., Gilbert E. Botulinum neurotoxin A decreases infiltrating cutaneous lymphocytes and improves acanthosis in the KC-Tie2 mouse model. J Invest Dermatol 2012, 132:1927-1930.
107. Ostrowski S.M., Belkadi A., Loyd C.M., Diaconu D., Ward N.L. Cutaneous denervation of psoriasiform mouse skin improves acanthosis and inflammation in a sensory neuropeptide-dependent manner. J Invest Dermatol 2011, 131:1530-1538.
108. Ahlehoff O., Skov L., Gislason G., Lindhardsen J., Kristensen S.L., Iversen L., et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med 2012.
109. de Boer O.J., van der Meer J.J., Teeling P., van der Loos C.M., Idu M.M., van Maldegem F., et al. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol 2010, 220:499-508.
110. Eid R.E., Rao D.A., Zhou J., Lo S.F., Ranjbaran H., Gallo A., et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 2009, 119:1424-1432.
111. Cheng X., Yu X., Ding Y.J., Fu Q.Q., Xie J.J., Tang T.T., et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol 2008, 127:89-97.
112. Sugiyama H., Gyulai R., Toichi E., Garaczi E., Shimada S., Stevens S.R., et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005, 174:164-173.
113. Gao Q., Jiang Y., Ma T., Zhu F., Gao F., Zhang P., et al. A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J Immunol 2010, 185:5820-5827.
114. Smith E., Prasad K.M., Butcher M., Dobrian A., Kolls J.K., Ley K., et al. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 2010, 121:1746-1755.
115. Xie J.J., Wang J., Tang T.T., Chen J., Gao X.L., Yuan J., et al. The Th17/Treg functional imbalance during atherogenesis in apoE(-/-) mice. Cytokine 2010, 49:185-193.
116. Usui F., Kimura H., Ohshiro T., Tatsumi K., Kawashima A., Nishiyama A., et al. Interleukin-17 deficiency reduced vascular inflammation and development of atherosclerosis in western diet-induced apoE-deficient mice. Biochem Biophys Res Commun 2012, 420:72-77.
117. Erbel C., Chen L., Bea F., Wangler S., Celik S., Lasitschka F., et al. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. J Immunol 2009, 183:8167-8175.